Introduction
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis after interventional cardiology and is often given to patients with acute coronary syndromes without ST-segment elevation w1x. The drug is commonly given in combination with aspirin w1x. An increasing number of patients are presented to emergent or urgent coronary artery bypass grafting (CABG) still being on antiplatelet medication and several studies have shown that preoperative administration of clopidogrel increases the risk of bleeding complications following CABG w2x.
Aprotinin (Trasylol) is a potent antifibrinolytic agent and numerous publications have documented a significant reduction in postoperative bleeding and transfusion requirements after routine cardiac surgery w3x. The drug also preserves the platelet receptors glycoprotein 1b (GP1b), which are responsible for formation of platelets clots as the first step of haemostasis after surgery w4x. Therefore, a rationale exists for giving aprotinin to patients in whom platelet function is disturbed by clopidogrel before the operation. The most common practice is to administer aprotinin in high doses immediately before surgery, during the operation, and during the first postoperative hours w3x. There has been some reports, however, indicating that there is a haemostatic effect of the drug, even when given in smaller doses during or after the operation w5, 6x. The aim of the study was to evaluate the clinical outcomes in clopidogrel patients exposed to the standard high dose aprotinin regimen compared with a low postoperative dose aprotinin given after CABG.
Methods

Patients
During the time period from March 2004 to November 2007, all patients admitted for CABG and receiving clopidogrel (plus or minus aspirin) -6 days preoperatively were included in the study. Exclusion criteria were re-do operations, renal failure (creatinine )180 mmolyl), and patients receiving other drugs influencing the coagulation system, like heparin, low molecular heparin, tirofiban, or warfarin. It was thought unethical to include a control group receiving placebo, since the risk of bleeding in patients on clopidogrel was well known w2x at the start of the study. The institution did not require informed consent from the patients since aprotinin was universally accepted for clinical use during cardiac surgery throughout the study period.
Operation and cardiopulmonary bypass (CPB)
All patients were operated on-pump. Standard cannulation included one aortic cannula and one two-stage venous cannula. The aorta was cross-clamped during performance of the distal anastomoses and cold, crystalloid cardioplegia was given into the aortic root. The proximal anastomoses were performed during partial occlusion of the ascending aorta while the patient was being re-warmed.
The extracorporeal circulation was performed with roller pumps with the pulsatile flow control. Mild hypothermia (blood temperature, 32 8C) was instituted immediately having started bypass.
Group A
25,000 kallikrein inhibitor unit (KIU)ykg (2.5 mlykg) was given in a central venous line before CPB, after insertion of the venous and aortic cannula. A test dose of 1 ml was given initially, to exclude potential adverse effects.
25,000 KIUykg (2.5 mlykg) was added to the priming of the heart-lung machine.
25,000 KIUykg (2.5 mlykg) was administered through a central venous line over the next 5 h (0.5 mlykgyh).
The maximum dose should not exceed a total of 6 million KIU.
Group B
25,000 KIUykg (2.5 mlykg) was given in a central venous line, starting after termination of CPB and administration of protamine. A test dose of 1 ml was given as for Group A. The maximum dose was 2 million KIU.
The standard CPB technique of our institution includes completely heparin-coated circuits wCarmeda Bio-Active Surface (CBAS), Medtronic Inc, Minneapolis, MN, USAx and reduced systemic heparin with an activated clotting time (ACT) )250 s. This was continued for Group B. In Group A, however, the combination of intraoperative aprotinin and reduced heparin during bypass is shown to increase thrombin formation w7x. Therefore, in Group A, the patients were given a full heparin dose with an ACT )480 s. Protamine chloride was given in a ratio of 1.3 mg:1 mg heparin, with supplemental doses whenever needed to reach the preoperative ACT level.
A consistent blood conservation protocol, previously described in detail w8x, was applied to all patients. Normovolemic anaemia was accepted to a hematocrit level of 0.25 postoperatively; a level below this was considered an indication for allogeneic red blood cell transfusion.
Statistical analysis
Comparison of the two groups was done using MannWhitney U-test for continuous variables. Discrete variables were treated by means of contingency tables, with Yates' correction and Fisher's test performed when one of the expected cell values was -5. A P-0.05 was considered significant. All data were recorded prospectively and stored in a database.
Results
Altogether 399 patients fulfilled the inclusion criteria. This represents 17.4% of the total of 2288 patients referred to first-time CABG during the study period. The clinical variables were nearly identical between the two groups ( Table 1) . The patients were treated with aspirin in addition to clopidogrel in 89.9% of the patients in Group A and in 89.1% in Group B (n.s.). Aspirin was given until the day before surgery. The elapsed time between the last dose of clopidogrel and the operation was -24 h in 48% of the patients and -3 days in 83% of the patients, without intergroup differences.
Operative variables were similar without any significant statistical differences. In Group A and Group B the ischemic time was 31 min (14-72) vs. 34 min (6-105) (Ps0.43), the bypass time 51 min (18-90) vs. 53 min (21-165), respectively (Ps0.47). The median number of distal anastomoses was 4 (1-7) in both groups. At least one arterial graft was used in all but four patients.
The median mediastinal drainage was slightly lower in Group A compared with Group B (Ps0.04) (Table 2), but in both groups the amount of bleeding was considered favourable compared with daily clinical experience with patients without aprotinin, as well as reported by others w11x. During the study period, the median mediastinal drainage was 680 ml (range, 130-3760 ml) in patients not receiving aprotinin. The bleeding was not significantly higher in the patients having clopidogrel discontinued in the last 24 h vs. )24 h (495 ml vs. 450 ml in Group A, Table 2) . The overall postoperative course is outlined in Table 3 . The treatment with inotropic agents after the operation was significantly higher in Group A (Ps0.006). As for the renal function, the increase in postoperative creatinine was significantly higher in Group A than in Group B (Ps0.002). The 30-day mortality was four patients in Group A (one renal failure, one stroke and two with myocardial decompensationyarrhythmia) and one patient with stroke in Group B (n.s.)
Discussion
Clopidogrel in combination with aspirin is recommended as standard drug therapy for patients with acute coronary syndrome and for prevention of stent thrombosis after PCI w1x. Clopidogrel exposure within one week before CABG has in many studies been shown to increase postoperative bleeding and transfusion requirements w2, 11x. This has triggered the use of various drugs to reduce bleeding, like the antifibrinolytic agents tranexamic acid and aminocaproic acid. However, these drugs do not affect the platelet function, which is the main target for treatment with clopidogrel. Aprotinin, an antifibrinolytic serine protease inhibitor, has been used for many years in elective and emergent surgery, both routinely and selectively in patients with increased risk of bleeding w3x. In addition to the antifibrinolytic effects, aprotinin preserves the adhesive capacity of platelets during CPB, expressed by the amount of platelet membrane GP1b w4x. A randomized placebocontrolled study published by van der Linden et al. w11x could demonstrate decreased bleeding and less need for transfusions in CABG patients on clopidogrel, receiving a full-dose aprotinin regimen. However, concerns still exist regarding the risk of thrombotic and renal complications with high doses of aprotinin.
The present data represent, to the best of our knowledge, the first randomized clinical trial, comparing a standard high dose perioperative dose of aprotinin with a low postoperative dose in the subset of CABG patients receiving clopidogrel preoperatively. The most striking results were the effectiveness and safety of the low postoperative dose of the drug. The postoperative bleeding was moderate in both groups. The statistically significant difference in favour of the high dose regimen was hardly of any clinical significance. In fact, the most important bleeding complications, i.e. the rate of re-exploration and blood transfusions, were nearly identical in the two groups.
The ACT during CPB was kept different in the two groups, due to the institutional technique of completely heparincoated cardiopulmonary circuits allowing reduced systemic heparinization. However, the results obtained with the low aprotinin dose may be generalized, since the drug was given after neutralizing heparin with protamine and after having achieved a normal ACT.
The renal impairment of aprotinin given in high doses is well known w3, 12x, and this was confirmed in our study. This is of particular concern, since only patients with normalysubnormal kidney function were included in the trial. It may be anticipated that patients with preoperative renal insufficiency would have been doing even worse if enrolled into our study design.
More patients in the high dose group needed inotropic support during the first postoperative hours. The rate of postoperative myocardial infarction, however, was low and without intergroup differences, which is comparable with other studies w3, 12x. The difference in 30-day mortality (0.5% vs. 2.0%) was not statistically significant, but the limited number of patients precludes reliable conclusions.
The safety of aprotinin has received particular attention during the last couple of years. Although recent reports could not confirm increased risks for mortality, stroke, myocardial infarction w12x or negative affects on short-or medium-term survival w13x, several other retrospective studies has reported increased risk of death among patients receiving aprotinin w9, 14, 15x. Even more concerning were the data from the BART trial, the multicenter study comparing aprotinin, tranexamic acid and aminocaproic acid, showing a strong and consistent negative mortality trend associated with aprotinin, as compared to the two other drugs w10x. As a consequence of the results from these studies, the drug was suspended from the market in November 2007.
The results from the present study may indicate that patients presenting with platelet defects, due to clopidogrel represent a subgroup of CABG patients which can safely be treated with a low postoperative dose of aprotinin. This advantage must be kept in mind if the alternative is transfusion of bank blood. Further, this particular administration may be of interest if future analogues to aprotinin will be introduced.
